NM_004481.5:c.118G>C

Variant summary

Our verdict is Likely benign. The variant received -1 ACMG points: 2P and 3B. PM2BP4_ModerateBS1_Supporting

The NM_004481.5(GALNT2):​c.118G>C​(p.Gly40Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000642 in 1,246,932 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).

Frequency

Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000055 ( 0 hom. )

Consequence

GALNT2
NM_004481.5 missense

Scores

2
17

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: 0.302

Publications

0 publications found
Variant links:
Genes affected
GALNT2 (HGNC:4124): (polypeptide N-acetylgalactosaminyltransferase 2) This gene encodes a member of the glycosyltransferase 2 protein family. Members of this family initiate mucin-type O-glycoslation of peptides in the Golgi apparatus. The encoded protein may be involved in O-linked glycosylation of the immunoglobulin A1 hinge region. This gene may influence triglyceride levels, and may be involved Type 2 diabetes, as well as several types of cancer. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2014]
GALNT2 Gene-Disease associations (from GenCC):
  • congenital disorder of glycosylation, type iit
    Inheritance: AR Classification: STRONG Submitted by: ClinGen, Labcorp Genetics (formerly Invitae), PanelApp Australia, Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -1 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.23405755).
BS1
Variant frequency is greater than expected in population eas. GnomAd4 allele frequency = 0.0000133 (2/150788) while in subpopulation EAS AF = 0.000392 (2/5100). AF 95% confidence interval is 0.0000693. There are 0 homozygotes in GnomAd4. There are 2 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GALNT2NM_004481.5 linkc.118G>C p.Gly40Arg missense_variant Exon 1 of 16 ENST00000366672.5 NP_004472.1 Q10471-1A0A1L7NY50
GALNT2NR_120373.2 linkn.161G>C non_coding_transcript_exon_variant Exon 1 of 2
GALNT2NM_001291866.2 linkc.12+9320G>C intron_variant Intron 1 of 15 NP_001278795.1 Q10471G3V1S6B7Z6K2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GALNT2ENST00000366672.5 linkc.118G>C p.Gly40Arg missense_variant Exon 1 of 16 1 NM_004481.5 ENSP00000355632.4 Q10471-1
GALNT2ENST00000488903.1 linkn.140G>C non_coding_transcript_exon_variant Exon 1 of 2 2
GALNT2ENST00000494106.1 linkn.89+9320G>C intron_variant Intron 1 of 6 5

Frequencies

GnomAD3 genomes
AF:
0.0000133
AC:
2
AN:
150680
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000391
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.00
AC:
0
AN:
18306
AF XY:
0.00
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000547
AC:
6
AN:
1096144
Hom.:
0
Cov.:
22
AF XY:
0.00000754
AC XY:
4
AN XY:
530286
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
21760
American (AMR)
AF:
0.00
AC:
0
AN:
8868
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
13734
East Asian (EAS)
AF:
0.000171
AC:
4
AN:
23328
South Asian (SAS)
AF:
0.00
AC:
0
AN:
31412
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
31418
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
3350
European-Non Finnish (NFE)
AF:
0.00000217
AC:
2
AN:
920098
Other (OTH)
AF:
0.00
AC:
0
AN:
42176
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.625
Heterozygous variant carriers
0
1
2
2
3
4
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000133
AC:
2
AN:
150788
Hom.:
0
Cov.:
32
AF XY:
0.0000271
AC XY:
2
AN XY:
73678
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41342
American (AMR)
AF:
0.00
AC:
0
AN:
15162
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3454
East Asian (EAS)
AF:
0.000392
AC:
2
AN:
5100
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4812
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10088
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
292
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
67540
Other (OTH)
AF:
0.00
AC:
0
AN:
2088
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.550
Heterozygous variant carriers
0
0
1
1
2
2
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00
Hom.:
0
Bravo
AF:
0.0000302
ExAC
AF:
0.0000365
AC:
3

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

Inborn genetic diseases Uncertain:1
Jul 19, 2023
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.118G>C (p.G40R) alteration is located in exon 1 (coding exon 1) of the GALNT2 gene. This alteration results from a G to C substitution at nucleotide position 118, causing the glycine (G) at amino acid position 40 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.18
BayesDel_addAF
Benign
-0.082
T
BayesDel_noAF
Benign
-0.36
CADD
Benign
19
DANN
Benign
0.74
DEOGEN2
Benign
0.015
T
Eigen
Benign
-0.24
Eigen_PC
Benign
-0.26
FATHMM_MKL
Benign
0.40
N
LIST_S2
Benign
0.54
T
M_CAP
Pathogenic
0.96
D
MetaRNN
Benign
0.23
T
MetaSVM
Benign
-0.93
T
MutationAssessor
Benign
0.0
N
PhyloP100
0.30
PrimateAI
Pathogenic
0.84
D
PROVEAN
Benign
-0.17
N
REVEL
Benign
0.20
Sift
Benign
0.62
T
Sift4G
Benign
0.56
T
Polyphen
0.72
P
Vest4
0.23
MutPred
0.25
Loss of relative solvent accessibility (P = 0.0676);
MVP
0.83
MPC
0.65
ClinPred
0.24
T
GERP RS
2.9
PromoterAI
-0.017
Neutral
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
3.0
Varity_R
0.15
gMVP
0.57
Mutation Taster
=271/29
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs529277892; hg19: chr1-230203145; API